TrialJournal for immunotherapy of cancer2025

Early dynamics of clinical and laboratory parameters predict primary refractory disease in patients with metastatic urothelial carcinoma receiving atezolizumab.

Christopher J Graser et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.